Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias F Kramer

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
ACS Applied Materials & Interfaces|July 8, 2025
Biomimetic Apatite Nanoparticles and Microcrystalline Tyrosine as Biocompatible Vaccine Adjuvants: Performance in a Bluetongue Virus Sheep ModelEstela Pérez, Víctor Sebastián, Ana Rodríguez-Largo, et al.
The Journal of Allergy and Clinical Immunology|December 24, 2019
Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergensFederico Storni, Andris Zeltins, Ina Balke, et al.
Allergy|February 5, 2025
Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III TrialStefan Zielen, Jonathan A Bernstein, Gunter J Sturm, et al.
Allergy|March 8, 2023
The next generation virus-like particle platform for the treatment of peanut allergyJan M Sobczak, Pascal S Krenger, Federico Storni, et al.
The World Allergy Organization Journal|January 6, 2026
Patient preference in allergen immunotherapy - Understanding the patient's viewSven Becker, Martin Feindor, Anke Graessel, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 9, 2022
Ameliorating Atopy by Compensating Micronutritional Deficiencies in Immune Cells: A Double-Blind Placebo-Controlled Pilot StudyTina Bartosik, Sebastian A Jensen, Sheriene M Afify, et al.
Allergy|July 18, 2025
The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence-Based ApproachOliver Pfaar, Ralph Mösges, Michael S Blaiss, et al.
Journal for Immunotherapy of Cancer|May 25, 2019
Correction to: Vaccination with nanoparticles combined with micro-adjuvants protects against cancerMona O Mohsen, Matthew D Heath, Gustavo Cabral-Miranda, et al.
Journal of Investigational Allergology & Clinical Immunology|November 24, 2025
Assessing the Allergenic Relevance of Vespula alascensis Venom: Implications for Venom ImmunotherapyBenjamin O Slusarenko, Klara F Borrmann, Claudia Knappe, et al.
Journal for Immunotherapy of Cancer|April 28, 2019
Vaccination with nanoparticles combined with micro-adjuvants protects against cancerMona O Mohsen, Matthew D Heath, Gustavo Cabral-Miranda, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
ACS Applied Materials & Interfaces|July 8, 2025
Biomimetic Apatite Nanoparticles and Microcrystalline Tyrosine as Biocompatible Vaccine Adjuvants: Performance in a Bluetongue Virus Sheep ModelEstela Pérez, Víctor Sebastián, Ana Rodríguez-Largo, et al.
The Journal of Allergy and Clinical Immunology|December 24, 2019
Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergensFederico Storni, Andris Zeltins, Ina Balke, et al.
Allergy|February 5, 2025
Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III TrialStefan Zielen, Jonathan A Bernstein, Gunter J Sturm, et al.
Allergy|March 8, 2023
The next generation virus-like particle platform for the treatment of peanut allergyJan M Sobczak, Pascal S Krenger, Federico Storni, et al.
The World Allergy Organization Journal|January 6, 2026
Patient preference in allergen immunotherapy - Understanding the patient's viewSven Becker, Martin Feindor, Anke Graessel, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 9, 2022
Ameliorating Atopy by Compensating Micronutritional Deficiencies in Immune Cells: A Double-Blind Placebo-Controlled Pilot StudyTina Bartosik, Sebastian A Jensen, Sheriene M Afify, et al.
Allergy|July 18, 2025
The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence-Based ApproachOliver Pfaar, Ralph Mösges, Michael S Blaiss, et al.
Journal for Immunotherapy of Cancer|May 25, 2019
Correction to: Vaccination with nanoparticles combined with micro-adjuvants protects against cancerMona O Mohsen, Matthew D Heath, Gustavo Cabral-Miranda, et al.
Journal of Investigational Allergology & Clinical Immunology|November 24, 2025
Assessing the Allergenic Relevance of Vespula alascensis Venom: Implications for Venom ImmunotherapyBenjamin O Slusarenko, Klara F Borrmann, Claudia Knappe, et al.
Journal for Immunotherapy of Cancer|April 28, 2019
Vaccination with nanoparticles combined with micro-adjuvants protects against cancerMona O Mohsen, Matthew D Heath, Gustavo Cabral-Miranda, et al.
Pageof 8